← back to search

Vindi Jurinović

LMU Klinikum ·
🔎 Find collaborators in Hematology · Pathology and Forensic Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Cancer Genomics and Diagnostics.
h-index
26
citations
4,618
works
135
NIH funding
primary concept
email

Recent publications

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders
Journal of Clinical Investigation 2025cited by 5position: middledoi
Does Size Outweigh Number in Predicting Survival After Pulmonary Metastasectomy for Soft Tissue Sarcoma? Insights from a Retrospective Multicenter Study
Annals of Surgical Oncology 2025cited by 5position: middledoi
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)
Leukemia 2025cited by 1position: middledoi
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma – a retrospective single-centre analysis
Acta Oncologica 2025cited by 1position: middledoi
Identification of a gene expression signature associated with brain metastasis in colorectal cancer
Clinical & Translational Oncology 2024cited by 8position: middledoi
Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – A retrospective multicenter study of the Bavarian university hospitals
European Journal of Surgical Oncology 2024cited by 7position: middledoi
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Leukemia 2023cited by 37position: middledoi
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
HemaSphere 2023cited by 35position: middledoi
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Journal of Clinical Oncology 2023cited by 32position: middledoi
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
Molecular Cancer 2023cited by 21position: middledoi
Risk Stratification of Patients with <i>RUNX1-</i>mutated Acute Myeloid Leukemia
Blood 2023cited by 1position: middledoi
Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences
medRxiv 2023cited by 1position: middledoi
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
Leukemia 2022cited by 15position: middledoi
Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
Blood 2022cited by 4position: middledoi
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
Nature Communications 2021cited by 21position: middledoi
CHOP but Not Bendamustine Reverses <i>EZH2</i> Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models
Blood 2021cited by 7position: middledoi
An <i>EZH2</i> Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of <i>EZH2</i> Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial
Blood 2021cited by 2position: middledoi
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma
Cell Reports 2020cited by 75position: middledoi
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
Leukemia 2020cited by 74position: middledoi
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Blood Advances 2020cited by 11position: middledoi
Clinical presentation and differential splicing of <i>SRSF2, U2AF1</i> and <i>SF3B1</i> mutations in patients with Acute Myeloid Leukaemia
medRxiv 2020cited by 1position: middledoi
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration
Journal of Clinical Oncology 2019cited by 157position: middledoi
Impact of age on clinical risk scores in follicular lymphoma
Blood Advances 2019cited by 26position: middledoi
Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
Scientific Reports 2019cited by 11position: middledoi
DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome
Blood 2019cited by 8position: middledoi
Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma
Blood 2019cited by 0position: middledoi
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group
Biology of Blood and Marrow Transplantation 2018cited by 96position: firstdoi
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Clinical Cancer Research 2018cited by 88position: middledoi
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
Scientific Reports 2018cited by 17position: middledoi
Impact of age on genetics and treatment efficacy in follicular lymphoma
Haematologica 2018cited by 12position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wolfgang Hiddemann · Deutsche Forschungsgemeinschaft15 papers (2013–2023)Tobias Herold · German Cancer Research Center12 papers (2013–2024)Karsten Spiekermann · German Cancer Research Center9 papers (2013–2020)Klaus H. Metzeler · Krankenhaus Barmherzige Brüder9 papers (2013–2020)Ulrich Mansmann · Institute for the Future9 papers (2013–2025)Martin Dreyling · Hospital Universitario 12 De Octubre8 papers (2014–2021)Oliver Weigert · München Klinik8 papers (2016–2021)Stefan K. Bohlander · University of Auckland8 papers (2013–2020)Bianka Ksienzyk · Munich Leukemia Laboratory (Germany)7 papers (2013–2020)Michael Unterhalt · Technical University of Munich7 papers (2016–2023)Philipp A. Greif · German Cancer Research Center7 papers (2013–2022)Eva Hoster · Zimmer Biomet (Netherlands)7 papers (2018–2023)Wolfgang E. Berdel · Klinik für Schlafmedizin6 papers (2013–2020)Nikola P. Konstandin · LMU Klinikum6 papers (2014–2020)Helmut Blum · Gene Therapy Laboratory5 papers (2013–2020)Jan Braess · Ludwig-Maximilians-Universität München5 papers (2018–2020)Stefan Krebs · Gene Therapy Laboratory5 papers (2013–2020)Maria Cristina Sauerland · Charité - Universitätsmedizin Berlin4 papers (2016–2020)Stefanos A. Bamopoulos · Max Delbrück Center4 papers (2018–2020)Alexander Graf · Augusta University4 papers (2013–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hematology · Pathology and Forensic Medicine →